A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control-Reference-Cited by-同舟云学术

A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control

Published:2021-02-17 Issue:6 Volume:23 Page:1242-1251
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kadowaki Takashi¹²,Seino Yutaka³⁴,Kaku Kohei⁵^ORCID,Okamoto Taro⁶^ORCID,Kameya Miho⁶,Sato Asako⁶,Hirano Tomona⁶,Oshima Nobuyuki⁶,Gantz Ira⁷^ORCID,O'Neill Edward A.⁷,Engel Samuel S.⁷^ORCID,

Affiliation:

1. Department of Prevention of Diabetes and Lifestyle‐Related Diseases, Graduate School of Medicine The University of Tokyo Tokyo Japan

2. Toranomon Hospital Tokyo Japan

3. Kansai Electric Power Hospital Osaka Japan

4. Kansai Electric Power Medical Research Institute Osaka Japan

5. Kawasaki Medical School Okayama Japan

6. Japan Development MSD K.K. Tokyo Japan

7. Merck Research Laboratories Merck & Co., Inc. Kenilworth New Jersey USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine